143 related articles for article (PubMed ID: 16210793)
1. Effects of hypoxic cell radiosensitizer doranidazole (PR-350) on the radioresponse of murine and human tumor cells in vitro and in vivo.
Yahiro T; Masui S; Kubota N; Yamada K; Kobayashi A; Kishii K
J Radiat Res; 2005 Sep; 46(3):363-72. PubMed ID: 16210793
[TBL] [Abstract][Full Text] [Related]
2. Radiosensitivity of human pancreatic cancer cells in vitro and in vivo, and the effect of a new hypoxic cell sensitizer, doranidazole.
Shibamoto Y; Kubota T; Kishii K; Tsujitani M
Radiother Oncol; 2000 Aug; 56(2):265-70. PubMed ID: 10927148
[TBL] [Abstract][Full Text] [Related]
3. In vivo efficacy and pharmacokinetics of a new hypoxic cell radiosensitizer doranidazole in SUIT-2 human pancreatic cancer xenografted in mouse pancreas.
Matsuoka H; Shibamoto Y; Kubota T; Tsujitani M; Majima T
Oncol Rep; 2000; 7(1):23-6. PubMed ID: 10601585
[TBL] [Abstract][Full Text] [Related]
4. Increase in tumor oxygenation and potentiation of radiation effects using pentoxifylline, vinpocetine and ticlopidine hydrochloride.
Amano M; Monzen H; Suzuki M; Terai K; Andoh S; Tsumuraya A; Hasegawa T
J Radiat Res; 2005 Dec; 46(4):373-8. PubMed ID: 16394626
[TBL] [Abstract][Full Text] [Related]
5. The radiosensitizing effect of doranidazole on human colorectal cancer cells exposed to high doses of irradiation.
Zhang L; Gong A; Ji J; Wu Y; Zhu X; Lv S; Lv H; Sun X
BMC Cancer; 2007 Oct; 7():188. PubMed ID: 17919337
[TBL] [Abstract][Full Text] [Related]
6. Phase Ia study of a hypoxic cell sensitizer doranidazole (PR-350) in combination with conventional radiotherapy.
Nemoto K; Shibamoto Y; Ohmagari J; Baba Y; Ebe K; Ariga H; Takai Y; Ouchi A; Sasai K; Shinozaki M; Tsujitani M; Sakaguchi M; Yamada S; Sakamoto K
Anticancer Drugs; 2001 Jan; 12(1):1-6. PubMed ID: 11272282
[TBL] [Abstract][Full Text] [Related]
7. Enhanced local tumour control after single or fractionated radiation treatment using the hypoxic cell radiosensitizer doranidazole.
Murata R; Tsujitani M; Horsman MR
Radiother Oncol; 2008 Jun; 87(3):331-8. PubMed ID: 18375007
[TBL] [Abstract][Full Text] [Related]
8. Effect of a hypoxic cell sensitizer doranidazole on the radiation-induced apoptosis of mouse L5178Y lymphoma cells.
Aoki M; Furusawa Y; Shibamoto Y; Kobayashi A; Tsujitani M
J Radiat Res; 2002 Jun; 43(2):161-6. PubMed ID: 12238330
[TBL] [Abstract][Full Text] [Related]
9. Preclinical study on hypoxic radiosensitizing effects of glycididazole in comparison with those of doranidazole
Yasui H; Kubota N; Nishizumi J; Sakai Y; Yamamori T; Inanami O
Oncol Lett; 2018 Feb; 15(2):1993-1998. PubMed ID: 29434899
[TBL] [Abstract][Full Text] [Related]
10. The prospective application of a hypoxic radiosensitizer, doranidazole to rat intracranial glioblastoma with blood brain barrier disruption.
Yasui H; Asanuma T; Kino J; Yamamori T; Meike S; Nagane M; Kubota N; Kuwabara M; Inanami O
BMC Cancer; 2013 Mar; 13():106. PubMed ID: 23496909
[TBL] [Abstract][Full Text] [Related]
11. Effects of oxygen on intrinsic radiation sensitivity: A test of the relationship between aerobic and hypoxic linear-quadratic (LQ) model parameters.
Carlson DJ; Stewart RD; Semenenko VA
Med Phys; 2006 Sep; 33(9):3105-15. PubMed ID: 17022202
[TBL] [Abstract][Full Text] [Related]
12. Reevaluation of the radiosensitizing effects of sanazole and nimorazole in vitro and in vivo.
Sugie C; Shibamoto Y; Ito M; Ogino H; Suzuki H; Uto Y; Nagasawa H; Hori H
J Radiat Res; 2005 Dec; 46(4):453-9. PubMed ID: 16394636
[TBL] [Abstract][Full Text] [Related]
13. Radiation-chemical properties of the hypoxic cell radiosensitizer doranidazole (PR-350).
Kuwabara M; Iida Y; Inanami O; Sawamura S; Yokoyama K; Tsujitani M
J Radiat Res; 2002 Mar; 43(1):77-88. PubMed ID: 12056332
[TBL] [Abstract][Full Text] [Related]
14. Combination of EGFR/HER2 tyrosine kinase inhibition by BIBW 2992 and BIBW 2669 with irradiation in FaDu human squamous cell carcinoma.
Schütze C; Dörfler A; Eicheler W; Zips D; Hering S; Solca F; Baumann M; Krause M
Strahlenther Onkol; 2007 May; 183(5):256-64. PubMed ID: 17497097
[TBL] [Abstract][Full Text] [Related]
15. Reduction of tumor hypoxia and inhibition of DNA repair by nicotinamide after irradiation of SCCVII murine tumors and normal tissues.
Zheng H; Olive PL
Cancer Res; 1996 Jun; 56(12):2801-8. PubMed ID: 8665517
[TBL] [Abstract][Full Text] [Related]
16. Detection of hypoxic cells in murine tumors using the comet assay: comparison with a conventional radiobiological assay.
Shibuya K; Sasai K; Xie X; Utsumi H; Shibata T; Hiraoka M
Jpn J Cancer Res; 1999 Aug; 90(8):880-6. PubMed ID: 10543261
[TBL] [Abstract][Full Text] [Related]
17. Reoxygenation in the SCCVII tumor after KU-2285 sensitization plus single or fractionated irradiation.
Shibamoto Y; Kitakabu Y; Murata R; Oya N; Shibata T; Sasai K; Takahashi M; Abe M
Int J Radiat Oncol Biol Phys; 1994 Jun; 29(3):583-6. PubMed ID: 8005819
[TBL] [Abstract][Full Text] [Related]
18. SR 4233: a tumor specific radiosensitizer active in fractionated radiation regimes.
Brown JM; Lemmon MJ
Radiother Oncol; 1991; 20 Suppl 1():151-6. PubMed ID: 2020764
[TBL] [Abstract][Full Text] [Related]
19. Numb/Notch signaling pathway modulation enhances human pancreatic cancer cell radiosensitivity.
Bi YL; Min M; Shen W; Liu Y
Tumour Biol; 2016 Nov; 37(11):15145-15155. PubMed ID: 27677287
[TBL] [Abstract][Full Text] [Related]
20. The radiosensitizing effects of hypoxic cell sensitizer on SCCVII tumors in mice evaluated by highly accurate colony formation assay assisted by microcomputer.
Ono K; Akuta K; Masunaga S; Kinashi Y; Suzuki M
Nihon Igaku Hoshasen Gakkai Zasshi; 1996 Dec; 56(14):1066-70. PubMed ID: 9014470
[No Abstract] [Full Text] [Related]
[Next] [New Search]
